PMN ProMIS Neurosciences Inc.
Financings ·
ProMIS filed a $50,000,000 base shelf on Form S-3 and an at-the-market agreement with H.C. Wainwright & Co. for up to $17,988,524 of common shares, at a commission of up to 3.0%. The stock closed at $0.628 on August 11, 2025, and the supplement does not explain its float figures.
ProMIS now has until December 29, 2025 to lift its share price to at least $1.00. It said it may effect a reverse stock split if necessary.
ProMIS Neurosciences has in-licensed a patented technology platform to develop antibody therapies, therapeutic vaccines and other therapies derived from antibodies for neurodegenerative diseases and other misfolded protein diseases. The EpiSelect platform uses computational modeling to identify conformational epitopes that are exposed on toxic, misfolded forms of a protein but not on the properly folded form. Antibodies raised against these epitopes are designed to target the disease-causing form without interfering with the healthy protein, and are humanized for potential use in patients. The text names Alzheimer's disease, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, Parkinson's disease, progressive supranuclear palsy, corticobasal degeneration and schizophrenia as conditions the platform may address. The lead program, PMN310, is in the PRECISE-AD Phase 1b trial for Alzheimer's disease, with a blinded interim analysis anticipated in early third quarter 2026 and top-line data anticipated in early 2027. The pipeline chart lists programs in ALS, FTD, PD, DLB and HD, and the company says it is evaluating partnership and business development opportunities.
| Product or program | What it is | Stage |
|---|---|---|
| PMN310 | Antibody for Alzheimer's disease, tested in the PRECISE-AD trial | Phase 1b |
| EpiSelect platform | Computational platform identifying epitopes on misfolded proteins for antibody design | in-licensed platform technology |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $33.4 million | $10.6 million |
| Net income (loss) | -$39.7 million | $2.8 million |
| Cash from operations | -$28.1 million | -$27.2 million |
| Cash and equivalents | $6.1 million | $13.3 million |
| Short-term investments | $33,753 | $33,051 |
Our latest story on this, dated Jul 7, 2025: "ProMIS Neurosciences gets second 180-day period to meet Nasdaq bid price rule". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 13, 2025: "ProMIS Neurosciences files $50,000,000 shelf and up to $17,988,524 share sales plan". The story links the filing or release it is based on. Read the story.
ProMIS Neurosciences Inc. trades under the ticker PMN on NASDAQ.
ProMIS Neurosciences Inc. is listed on NASDAQ. Our directory also records these other listings: LSX:A41MFQ.
The SEC Central Index Key (CIK) for ProMIS Neurosciences Inc. is 1374339. Its filings are on SEC EDGAR.
8,967,693 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13.
Our directory records ProMIS Neurosciences Inc. under Canada.
Our directory classifies ProMIS Neurosciences Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for ProMIS Neurosciences Inc. is CA74346M5054.
aibio.space lists ProMIS Neurosciences Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as Z4.
ProMIS Neurosciences has in-licensed a patented technology platform to develop antibody therapies, therapeutic vaccines and other therapies derived from antibodies for neurodegenerative diseases and other misfolded protein diseases. The EpiSelect platform uses computational modeling to identify conformational epitopes that are exposed on toxic, misfolded forms of a protein but not on the properly folded form.
PMN310: Antibody for Alzheimer's disease, tested in the PRECISE-AD trial Stage: Phase 1b.
EpiSelect platform: Computational platform identifying epitopes on misfolded proteins for antibody design Stage: in-licensed platform technology.
ProMIS Neurosciences Inc. reported a net loss of $39.7 million for the fiscal year ended Dec 31, 2025, and used $28.1 million of cash in operations, per its annual report to the SEC.
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio